Thereafter, PRL-3 itself again may be considered as a potential therapeutic target in diseases due to epigenetic abnormal regulation, including various types of cancer, rather than HDAC4 that would raise generally intrinsic side effect if targeted. The gene discussed is PTP4A3; the disease is cancer.